Actinium Pharmaceuticals, Inc.
https://www.actiniumpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Actinium Pharmaceuticals, Inc.
Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout
The acquisition of Mariana will complement Novartis’s lutetium-based radioligand therapies with candidates using actinium. Lilly, Bristol and AstraZeneca all have made recent high-priced buys in the space.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?
Abdera Comes Out Of Stealth With Radiopharmaceutical-Specialized Antibody Approach
The company has sought to develop antibodies purpose-built for delivering radiotherapy rather than repurposing existing antibodies for that purpose, as some other players have done.
New Data Bolster Prospects For Actinium's Radioligand
The US firm has announced positive survival data from a Phase III trial of it radioligand therapy, Iomab-B, in acute myeloid leukemia patients prior to bone transplant, improving its cost-effectiveness case and commercial strategy.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Cactus Ventures, Inc. (CTVN)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice